Sugi Predict

Sugi Predict / Targets / CAPRIN1

CAPRIN1

Caprin-1 · Q14444 · CAPRIN1 on Sugi Atlas →

0 patent compounds predicted against CAPRIN1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CAPRIN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Clinical and Biochemical Features for the Identification of Dominant Calpainopathies nanUNKNOWN
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests nanUNKNOWN
LGMD R1 Natural History Study nanACTIVE_NOT_RECRUITING
Genomic Analysis of Families With a History of Discordant Cancers nanRECRUITING
Tecfidera Diffusion Tensor Imaging nanCOMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Brain Involvement in Dystrophinopathies Part 2 nanCOMPLETED
Functional Genomic Influences on Disease Progression and Outcome in Sepsis nanUNKNOWN
Autoimmune Dysregulation in Pigmentary Glaucoma nanCOMPLETED
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
Genetics and Epigenetics of Graves' Orbitopathy nanCOMPLETED
Urine Concentration of S100B in Extremely Premature Infants nanCOMPLETED
Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression nanRECRUITING
Leukocyte Morphological Parameters as Prognostic Markers in CAP nanUNKNOWN
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs nanUNKNOWN
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals nanUNKNOWN
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Biomarker for Peritoneal Ultrafiltration Failure nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Vagal Stimulation Therapy and Preeclampsia nanRECRUITING
Genetic Determinants of Exercise-Induced Muscle Damage (POLYGENDOMUS) nanRECRUITING
Capturing Early Events in Human Parturition nanUNKNOWN
Family Blood Pressure Program - GENOA nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CAPRIN1 binder may also engage these)

ProteinNameSimilarity
Q60865 — 1.000 Q60865 →
Q5M9G3 — 1.000 Q5M9G3 →
Q1LZB6 — 1.000 Q1LZB6 →
Q8K0V4 — 0.991 Q8K0V4 →
Q80XI3 — 0.990 Q80XI3 →
P97868 — 0.990 P97868 →
Q9ULH7 — 0.989 Q9ULH7 →
Q5CZI8 — 0.989 Q5CZI8 →
Q6NZJ6 — 0.989 Q6NZJ6 →
Q09801 — 0.989 Q09801 →
Q9H7E2 — 0.988 Q9H7E2 →
F4IUY8 — 0.988 F4IUY8 →
Q9I7D3 — 0.988 Q9I7D3 →
Q9LV14 — 0.988 Q9LV14 →
BAG3 BAG family molecular chaperone regulator 3 0.988 landscape →
A0JMU8 — 0.988 A0JMU8 →
Q9VIV2 — 0.988 Q9VIV2 →
Q71RC2 — 0.988 Q71RC2 →
Q6IMN6 — 0.988 Q6IMN6 →
PRRC2C Protein PRRC2C 0.988 landscape →
Q6E3D4 — 0.987 Q6E3D4 →
A0A0R4IZ84 — 0.987 A0A0R4IZ84 →
Q7ZXH3 — 0.987 Q7ZXH3 →
Q7TPM1 — 0.987 Q7TPM1 →
Q9BTA9 — 0.987 Q9BTA9 →
G5EGU9 — 0.987 G5EGU9 →
A5DH19 — 0.987 A5DH19 →
Q9FGK9 — 0.987 Q9FGK9 →
BMP2K BMP-2-inducible protein kinase 0.987 landscape →
Q2EJA0 — 0.987 Q2EJA0 →